Β-Hydroxythiofentanyl

{{Short description|Opioid analgesic drug}}

{{lowercasetitle}}

{{Drugbox

| drug_name = β-Hydroxythiofentanyl

| verifiedrevid = 410873709

| IUPAC_name = N-{1-[2-Hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropanamide

| image = Betahydroxythiofentanyl.svg

| width = 200px

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA = Schedule I

| legal_UK = Class A

| legal_US = Schedule I

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1474-34-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = MG6JW60TUG

| ATC_prefix = none

| ATC_suffix =

| PubChem = 62278

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 21106268

| C=20 | H=26 | N=2 | O=2 | S=1

| smiles = CCC(=O)N(c1ccccc1)C2CCN(CC2)CC(c3cccs3)O

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C20H26N2O2S/c1-2-20(24)22(16-7-4-3-5-8-16)17-10-12-21(13-11-17)15-18(23)19-9-6-14-25-19/h3-9,14,17-18,23H,2,10-13,15H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = GLAAETOTOUGGSB-UHFFFAOYSA-N

| synonyms =

}}

β-Hydroxythiofentanyl (beta-hydroxythiofentanyl) is an opioid analgesic that is an analog of fentanyl and thiofentanyl.

β-Hydroxythiofentanyl was sold briefly on the black market from around 1985,Valter K, Arrizabalaga P. Designer Drugs Directory (1998), p150. {{ISBN|0-444-20525-X}} before the introduction of the Federal Analog Act in 1986 which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.{{cite journal | vauthors = Henderson GL | year = 1988 | title = Designer Drugs: Past History and Future Prospects | journal = Journal of Forensic Sciences | volume = 33 | issue = 2| pages = 569–575 | doi = 10.1520/JFS11976J | pmid = 3286815 }} β-hydroxythiofentanyl was anecdotally said to be one of the more favored fentanyl analogs by opiate addicts{{cn|date=October 2023}}.

Side Effects

β-Hydroxythiofentanyl has effects and side effects similar to fentanyl. Side effects of fentanyl analogs include itching, nausea and potentially serious respiratory depression, which can be life-threatening.{{Citation needed|date=March 2024}}

Legal status

As of October 2015, β-hydroxythiofentanyl is a controlled substance in China.{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=zh | access-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=1 October 2015 | url-status=dead }}

As of May 2016, β-hydroxythiofentanyl was temporarily listed as a Schedule I controlled substance in the United States.{{cite web | url=https://www.gpo.gov/fdsys/pkg/FR-2016-05-12/pdf/2016-11219.pdf | title=Schedules of Controlled Substances: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl into Schedule I | publisher=Drug Enforcement Administration | date=12 May 2016}} A final ruling placing it in Schedule I was issued by the DEA on May 8, 2019 after a 1 year notice of proposed permanent scheduling.{{USC|5|556-557}} There were no petitions for hearings on the matter.{{cite journal |author1=Drug Enforcement Administration |title=Schedules of Controlled Substances: Placement of beta-Hydroxythiofentanyl in Schedule I |journal=Federal Register |date=May 8, 2019 |volume=84 |issue=89 |pages=20023–20027 |url=https://www.federalregister.gov/d/2019-09479 |access-date=7 March 2024 |publisher=Department of Justice |id=Docket No. DEA–484}}{{CodeFedReg |21|1308|subpart=b|11|17}}

See also

References